IA
TEVA icon

IFG Advisory’s Teva Pharmaceuticals TEVA Stock Holding History

IFG Advisory’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$12.7K Buy
374
+24
+7% +$799 ﹤0.01% 1775
2026
Q1 		$10.5K Buy
+350
New +$11.3K 0.03% 242

Other funds holding TEVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return
WCM Investment Management
WCM Investment Management Laguna Beach, California $55.2B AUM 57.07% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return

IFG Advisory's TEVA Position: Q2 2026 in Review

IFG Advisory increased its Teva Pharmaceuticals (TEVA) stake by 6.9% in Q2 2026, buying an estimated $799 and bringing the position to 374 shares worth $12.7K. The position accounts for ﹤0.01% of the portfolio, ranked #1775.

IFG Advisory first reported a position in TEVA in Q1 2026 and has held it in 2 quarters since. 673 funds tracked by Wall St. Rank hold TEVA as of Q2 2026.

  • IFG Advisory held 374 shares of Teva Pharmaceuticals worth $12.7K as of Q2 2026.
  • IFG Advisory bought 24 Teva Pharmaceuticals shares in Q2 2026, an estimated $799.
  • Teva Pharmaceuticals made up ﹤0.01% of IFG Advisory's portfolio in Q2 2026, its #1775 holding.
  • IFG Advisory first reported a position in Teva Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • 673 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2026.

Based on IFG Advisory's 13F filing for Q2 2026, filed 14 Aug 2026.